Loading…
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-83M | $-46M | $-62M | -56.3% | - | - |
| 2024 | $0M | $-70M | $-36M | $-47M | -57.9% | - | - |
| 2023 | $0M | $-43M | $-117M | $-40M | -1616.8% | - | - |
| 2022 | $0M | $-39M | $-88M | $-28M | -104.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 39.78 | 43 | 70.58 | 83.25 |
| Operating Income | -39.78 | -43 | -70.58 | -83.25 |
| EBITDA | -39.41 | -42.63 | -70.22 | -82.94 |
| EBIT | -39.78 | -43 | -70.58 | -83.25 |
| Pretax Income | -87.97 | -116.54 | -35.75 | -45.58 |
| Tax Provision | 0 | 0 | 0.43 | 0.04 |
| Net Income | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income Common Stockholders | -87.97 | -116.54 | -36.18 | -45.62 |
| Total Expenses | 39.78 | 43 | 70.58 | 83.25 |
| Research And Development | 27.08 | 30.31 | 51.96 | 66.27 |
| Selling General And Administration | 12.70 | 12.69 | 18.61 | 16.98 |
| Normalized EBITDA | 9.24 | 33.59 | -101.12 | -116.39 |
| Normalized Income | -39.32 | -40.33 | -60.59 | -72.04 |
| Basic EPS | -6.16 | -3.74 | -0.66 | -0.52 |
| Diluted EPS | -6.16 | -3.74 | -0.66 | -0.52 |
| Tax Effect Of Unusual Items | 0 | 0 | 6.49 | 7.02 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Total Unusual Items | -48.65 | -76.21 | 30.90 | 33.45 |
| Total Unusual Items Excluding Goodwill | -48.65 | -76.21 | 30.90 | 33.45 |
| Net Income From Continuing Operation Net Minority Interest | -87.97 | -116.54 | -36.18 | -45.62 |
| Reconciled Depreciation | 0.37 | 0.37 | 0.36 | 0.31 |
| Net Interest Income | 0 | 0 | 0 | 0 |
| Net Income From Continuing And Discontinued Operation | -87.97 | -116.54 | -36.18 | -45.62 |
| Total Operating Income As Reported | -88.43 | -43 | 0 | 0 |
| Diluted Average Shares | 14.29 | 24.62 | 48.54 | 81.84 |
| Basic Average Shares | 14.29 | 24.62 | 48.54 | 81.84 |
| Diluted NI Availto Com Stockholders | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income Including Noncontrolling Interests | -87.97 | -116.54 | -36.18 | -45.62 |
| Net Income Continuous Operations | -87.97 | -116.54 | -36.18 | -45.62 |
| Other Income Expense | -48.19 | -73.54 | 34.82 | 37.67 |
| Other Non Operating Income Expenses | 0.46 | 2.67 | 3.92 | 4.22 |
| Special Income Charges | -48.65 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 48.65 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 0 |
| Gain On Sale Of Security | 0 | -76.21 | 30.90 | 33.45 |
| Net Non Operating Interest Income Expense | 0 | 0 | 0 | 0 |
| General And Administrative Expense | 12.70 | 12.69 | 18.61 | 16.98 |
| Other Gand A | 12.70 | 12.69 | 6.35 | 7.24 |
| Salaries And Wages | 0 | 0 | 12.26 | 9.74 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc.this co. | ELDN | $266M | - | 1.84 | -56.3% | - |
| RxSight, Inc. | RXST | $282M | - | 1.02 | -14.1% | -1.42 |
| Foghorn Therapeutics Inc. | FHTX | $279M | - | -2.49 | 68.5% | -2.05 |
| Editas Medicine, Inc. | EDIT | $276M | - | 10.11 | -586.6% | -1.57 |
| Accendra Health, Inc. | ACH | $267M |
| - |
| -0.58 |
| 238.8% |
| 5.96 |
| TriSalus Life Sciences, Inc. | TLSI | $262M | - | -6.29 | 115.8% | -10.46 |
| Coherus Oncology, Inc. | CHRS | $261M | - | 3.45 | 275.4% | -0.83 |
| Codexis, Inc. | CDXS | $255M | - | 5.04 | -87.0% | -7.57 |
| Alector, Inc. | ALEC | $255M | - | 8.27 | -466.3% | -0.23 |
| Peer Median | - | - | 2.24 | 27.2% | -1.50 | |